Saale-Apotheke Dr. Christian Wegner e.Kfm
Saale-Apotheke Dr. Christian Wegner e.Kfm is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Treatment Phase.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Study protocol title: A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed Rotigotine 12 mg/24 h transdermal patch in patients with Parkinson’s disease
Sponsor Luye Pharma Switzerland AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Saale-Apotheke Dr. Christian Wegner e.Kfm?
The 2026-10-09 snapshot links Saale-Apotheke Dr. Christian Wegner e.Kfm to 5 distinct CTIS trials. Recorded services include Medicinal product management, AxMP supply, Central Pharmacy, IMP shipment to patient. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Saale-Apotheke Dr. Christian Wegner e.Kfm?
The most frequently recorded therapeutic areas are Neurology, Solid Tumor Oncology, Urology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Saale-Apotheke Dr. Christian Wegner e.Kfm conducted?
The linked trials record locations in 11 countries, including Germany, Spain, France, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Saale-Apotheke Dr. Christian Wegner e.Kfm delivered services.
What can this page tell me about Saale-Apotheke Dr. Christian Wegner e.Kfm's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Saale-Apotheke Dr. Christian Wegner e.Kfm. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Saale-Apotheke Dr. Christian Wegner e.Kfm.